---
格式版本: 2
标题: "A seamless dose-optimization design for monotherapy and combination therapy"
原文链接: "https://arxiv.org/abs/2608.18435"
发布日期: "2026-08-19"
发布时间校准状态: "found"
发布时间需复核: "否"
发布时间来源: "rule:local:strict_original_body"
发布时间证据: "**\\[v1\\]** Wed, 19 Aug 2026 02:00:14 UTC (248 KB)"
发布时间校准原因: "规则确认唯一严格发布时间，来源 local:strict_original_body"
发布时间校准置信度: "high"
发布时间候选数量: 18
发布时间严格候选数量: 6
发布时间原页读取状态: "source template page reused from URL open"
发布时间未找到原因: ""
发布时间校准时间: "2026-08-20T15:52:23+08:00"
发布时间仲裁状态: "skipped"
发布时间仲裁尝试次数: 0
发布时间仲裁耗时毫秒: 0
发现时间: "2026-08-20T15:48:16+08:00"
入库时间: "2026-08-20T07:52:23.574Z"
来源平台: "arXiv 学术论文搜索"
搜索渠道: "source_template"
搜索词: "https://arxiv.org/search/?query=model%20fit&searchtype=all"
匹配关键词:
  - "model fit"
  - "performance"
相关厂家:
  []
相关专家:
  []
内容类型: "网页"
抓取工具: "Free Fetch + Defuddle"
清洗工具: "Defuddle Markdown + Defuddle/Readability 正文提取"
原始附件:
  []
AI优质: "否"
AI打分: 8
AI分档: "非优质"
AI质检状态: "不通过"
AI打分理由: "论文主题为肿瘤药物剂量优化设计，属于统计学/医学领域，与超节点、AI Rack、机柜级AI基础设施等完全无关。无相关技术、商业或部署信号。来源权威但内容不相关。"
AI质检模型: "ali-deepseek-v4-flash"
AI质检时间: "2026-08-20T15:58:05+08:00"
AI主题相关性: 0
AI来源权威性: 5
AI新颖性: 1
AI技术细节: 2
AI商业部署信号: 0
AI完整性: 0
AI摘要: "这篇论文提出一种无缝剂量优化设计，可基于疗效和毒性结果，通过自适应子试验和患者回填同时评估单药疗法与联合疗法；该模型辅助框架采用预设贝叶斯最优边界，无需实时模型拟合，模拟研究显示其在当代肿瘤学多种剂量反应模式下表现稳健。"
AI摘要模型: "ali-deepseek-v4-flash"
AI摘要时间: "2026-09-07T03:18:41.831Z"
采集批次: "2026年8月20日14点19分32秒"
采集批次ID: "20260820-141932-079"
去重键: "https://arxiv.org/abs/2608.18435"
---

## Statistics > Methodology

## Title:A seamless dose-optimization design for monotherapy and combination therapy

Authors:[Kentaro Takeda](https://arxiv.org/search/stat?searchtype=author&query=Takeda,+K), [Masahiro Kojima](https://arxiv.org/search/stat?searchtype=author&query=Kojima,+M)

[View PDF](https://arxiv.org/pdf/2608.18435) [HTML (experimental)](https://arxiv.org/html/2608.18435v1)

> Abstract:The emergence of molecular-targeted agents and immune-oncology therapies has fundamentally transformed oncology drug development, necessitating evolution beyond traditional dose-finding approaches designed for cytotoxic agents. While conventional agents exhibit predictable monotonic dose-response relationships, novel anticancer agents often demonstrate plateau-effect patterns where higher doses may compromise therapeutic benefit, requiring identification of optimal biological doses that balance efficacy and tolerability. The FDA's Project Optimus initiative emphasizes comprehensive dose optimization through parallel randomized cohorts and patient backfilling to better understand pharmacological profiles across multiple dose levels. Contemporary drug development increasingly prioritizes combination therapy alongside monotherapy evaluation, yet existing designs typically assume equivalent roles for both agents, diverging from clinical practice where novel agents combine with established treatments having limited dose options. This paper proposes a seamless dose-optimization design that adaptively evaluates both monotherapy and combination therapy based on efficacy and toxicity outcomes through adaptive subtrials with patient backfilling capabilities. The model-assisted framework employs predetermined Bayesian optimal boundaries, eliminating real-time model fitting while accommodating evaluation of both monotherapy and combination therapy and enabling sequential enrollment with strategic backfilling. Simulation studies demonstrate robust performance across diverse dose-response patterns relevant to contemporary oncology. The design addresses critical gaps between methodological assumptions and clinical reality, offering a practical approach that integrates monotherapy and combination therapy evaluation with efficacy-toxicity-based backfilling.

| Subjects: | Methodology (stat.ME) |
| --- | --- |
| Cite as: | [arXiv:2608.18435](https://arxiv.org/abs/2608.18435) \[stat.ME\] |
|  | (or [arXiv:2608.18435v1](https://arxiv.org/abs/2608.18435v1) \[stat.ME\] for this version) |
|  | [https://doi.org/10.48550/arXiv.2608.18435](https://doi.org/10.48550/arXiv.2608.18435) |

## Submission history

From: Masahiro Kojima Dr. \[[view email](https://arxiv.org/show-email/5a91ac3b/2608.18435)\]  
**\[v1\]** Wed, 19 Aug 2026 02:00:14 UTC (248 KB)

[Which authors of this paper are endorsers?](https://arxiv.org/auth/show-endorsers/2608.18435) | Disable MathJax ([What is MathJax?](https://info.arxiv.org/help/mathjax.html))